Wedbush analyst Laura Chico raised the firm’s price target on Biogen (BIIB) to $187 from $178 and keeps a Neutral rating on the shares. The firm notes the company delivered another top-/bottom-line beat in the Q4 2025/FY25 financial results. Wedbush commends the job the management team has done to realign the cost base. However, revenue growth drivers remain the critical missing piece for the turnaround story, it adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity
- Biogen price target raised to $233 from $217 at RBC Capital
- Biogen price target raised to $215 from $175 at TD Cowen
- Biogen price target raised to $196 from $165 at BMO Capital
- Biogen price target raised to $193 from $190 at Truist